The earnings call presented a mixed sentiment. While there were significant advancements in the expansion of addressable markets and successful litigation outcomes, the overall financial performance was hampered by a decline in total and equipment revenue due to international trade challenges.

Company Guidance

During the call, STRATA Skin Sciences provided guidance and insights into their strategic initiatives and financial performance for the third quarter of 2025. A significant highlight was the anticipated expansion of CPT codes for the XTRAC 308-nanometer excimer laser, effective January 1, 2027, which is expected to significantly broaden reimbursement eligibility to over 30 skin conditions and potentially triple the addressable patient market. The company noted an 8.5% increase in average gross billings per device to $5,981, marking the highest since 2022, while recurring revenue saw a 4.1% growth. Despite total revenue falling 20% to $6.9 million due to international challenges, STRATA maintained a gross profit margin of 60%. The Elevate360 program, implemented in 99 clinics, resulted in a 7% growth for participating partners. Additionally, the company is focused on international expansion, with initial placements in Mexico, and is actively pursuing litigation against LaserOptik to reclaim market share, having already brought back approximately two dozen devices. STRATA remains optimistic about the fourth quarter and the long-term growth opportunities presented by expanded reimbursement and international market penetration.

Expansion of CPT Codes

The historic expansion of CPT codes for STRATA's XTRAC 308-nanometer excimer laser, effective January 1, 2027, will expand reimbursement eligibility to include multiple inflammatory and autoimmune skin conditions, increasing the addressable market by threefold.

Elevate360 Program Success

Since the beginning of 2025, 99 clinics part of the Elevate360 program have seen an average growth of 7% year over year. The gross billings per device increased by 8.5% versus 2024, reaching the highest since 2022.

International Expansion

Regulatory approval and initial commercial placements of technologies in Mexico mark significant progress in international expansion.

Successful Litigation Outcomes

STRATA won an injunction against LaserOptik, limiting damage and allowing 20 clinics to return, contributing over $1 million in annual revenue.

Improved Financial Metrics

Adjusted EBITDA turned positive compared to negative $240,000 in the previous year, driven by lower operating expenses.

Strata Skin Sciences (SSKN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

SSKN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Mar 24, 2026	2025 (Q4)	-0.40 / -	-0.865	―	―	―
Nov 13, 2025	2025 (Q3)	-0.53 / <0.01	-0.192	102.08% (+0.20)	―
Aug 13, 2025	2025 (Q2)	-0.29 / -0.19	0.533	-134.90% (-0.72)	―
May 14, 2025	2025 (Q1)	-0.52 / -0.23	-0.432	47.22% (+0.20)	―
Mar 27, 2025	2024 (Q4)	-0.30 / -0.86	-0.416	-107.93% (-0.45)	―
Nov 13, 2024	2024 (Q3)	-0.45 / -0.19	0.397	-148.36% (-0.59)	―
Aug 14, 2024	2024 (Q2)	-0.70 / 0.53	-0.025	2232.00% (+0.56)	―
May 15, 2024	2024 (Q1)	-0.65 / -0.43	-0.205	-110.73% (-0.23)	―
Mar 27, 2024	2023 (Q4)	-0.20 / -0.42	0.45	-192.44% (-0.87)	―
Nov 14, 2023	2023 (Q3)	-0.40 / 0.40	-0.3	232.33% (+0.70)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

SSKN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Nov 13, 2025	$1.52	$1.36	-10.53%
Aug 13, 2025	$1.88	$1.81	-3.72%
May 14, 2025	$2.64	$2.68	+1.52%
Mar 27, 2025	$2.71	$2.69	-0.74%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Strata Skin Sciences Inc (SSKN) report earnings?

Strata Skin Sciences Inc (SSKN) is schdueled to report earning on Mar 24, 2026, After Close (Confirmed).

What is Strata Skin Sciences Inc (SSKN) earnings time?

Strata Skin Sciences Inc (SSKN) earnings time is at Mar 24, 2026, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is SSKN EPS forecast?

SSKN EPS forecast for the fiscal quarter 2025 (Q4) is -0.4.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing